Hexaminolevulinate hydrochloride is under clinical development by Jiangsu Yahong Meditech and currently in Phase III for Cervical Intraepithelial Neoplasia (CIN). According to GlobalData, Phase III drugs for Cervical Intraepithelial Neoplasia (CIN) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Hexaminolevulinate hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Hexaminolevulinate hydrochloride overview

Cevira (APL-1702) is under development for the treatment of cervical high grade squamous intraepithelial lesion (HSIL) caused by infection with all HPV subtypes. It is hexaminolevulinate (HAL) photodynamic therapy (PDT).

Jiangsu Yahong Meditech overview

Jiangsu Yahong Meditech (Jiangsu Meditech) discovers and develops drugs for the treatment of genitourinary tumors. The company’s pipeline products APL-1202 is an oral drug used to treat non-muscle-invasive bladder cancer; APL-1501 is an oral MetAP inhibitor used to treat drug-resistant UTIs and urinary system tumors; APL-1706 is a medication used to treat non-muscle-invasive bladder cancer; APL-1702 is a drug used to treat cervical high-grade squamous intraepithelial lesions; ASN-1764 is a medication used to treat triple-negative breast cancer and AT-012 is a medication used to treat ovarian cancer and breast cancer. The company develops APL-1401 and ASN-1733 to treat active ulcerative colitis and acinetobacter baumannii infection. Jiangsu Meditech is headquartered in Pudong, China.

For a complete picture of Hexaminolevulinate hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.